Many people try one, see how they feel, and decide from there with their nurse
Evidence-Supported Indications Adults with BMI 35 kg/m, or BMI 27 with at least one or more weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea Type 2 Diabetes: Adults requiring improved glycemic control this remains the foundation of the drug class and where the longest safety record exists Cardiovascular Risk Reduction: The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide in adults with overweight or obesity and established cardiovascular disease Metabolic Syndrome Presentations: Patients with non-alcoholic fatty liver disease, polycystic ovarian syndrome, and insulin resistance syndromes Binge Eating Disorder (BED) Emerging Data: Emerging evidence suggests GLP-1 medications may reduce binge frequency though this data remains preliminary and is discussed in detail below Why It Is Not "Cheating" The genetics of obesity are increasingly well-characterized
Zepbound saw an even more dramatic transformation after the addition of the sleep apnea indication, increasing its approval rates in Part D from 10% to 28% in half a year
To get the most out of this powerful antioxidant, it's important to avoid certain factors that can diminish its effectiveness
Plans vary widely, even within the same insurer
